Healthcare -
Medical - Care Facilities - NASDAQ - GB
$ 3.26
-3.55 %
$ 303 M
Market Cap
-1.64
P/E
1. INTRINSIC VALUE
Balance Sheet
COMPASS Pathways plc
| Current Assets | 201 M |
| Cash & Short-Term Investments | 165 M |
| Receivables | 21.8 M |
| Other Current Assets | 14.4 M |
| Non-Current Assets | 12.4 M |
| Long-Term Investments | 469 K |
| PP&E | 2.2 M |
| Other Non-Current Assets | 9.71 M |
| Current Liabilities | 34 M |
| Accounts Payable | 12.3 M |
| Short-Term Debt | 7.24 M |
| Other Current Liabilities | 14.5 M |
| Non-Current Liabilities | 25 M |
| Long-Term Debt | 25 M |
| Other Non-Current Liabilities | 1 |
EFFICIENCY
Earnings Waterfall
COMPASS Pathways plc
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 178 M |
| Operating Income | -178 M |
| Other Expenses | -23.1 M |
| Net Income | -155 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
COMPASS Pathways plc
| Net Income | -155 M |
| Depreciation & Amortization | 233 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 19.5 M |
| Change in Working Capital | 11.7 M |
| Others | 9.6 M |
| Free Cash Flow | -119 M |
Wall Street Analysts Price Targets
COMPASS Pathways plc
Wall Street analysts predict an average 1-year price target for CMPS of $23 , with forecasts ranging from
a
low of
$23 to a high of $23 .
CMPS Lowest Price Target
Wall Street Target
23 USD
605.52%
CMPS Average Price Target
Wall Street Target
23 USD
605.52%
CMPS Highest Price Target
Wall Street Target
23 USD
605.52%
4. DIVIDEND
ANALYSIS
CMPS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
COMPASS Pathways plc
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 2
9-12 MONTHS
16.1 M USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360
I am moving Compass Pathways plc from Strong Buy to Hold after phase 3 COMP005 data, as results met endpoints but disappointed market expectations. Upcoming catalysts include 26-week COMP006 phase 3 data in 2H 2026 and ongoing PTSD and anorexia programs, but risks remain if future data underwhelms. The treatment resistant depression market in the 7 major markets is expected to reach $6.70 billion by 2035.
seekingalpha.com
- 3 weeks ago
Compass Pathways' late-stage psilocybin trial targeting treatment-resistant depression meets primary endpoint
Compass Pathways (NASDAQ:CMPS) has reported positive results from its Phase 3 trial of its synthetic formulation of psilocybin, COMP360, in patients with treatment-resistant depression (TRD), with the trial meeting its primary endpoint. A single 25 mg dose of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in depression symptom severity compared to placebo, with a mean difference of 3.6 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) at week 6.
proactiveinvestors.com
- 3 weeks ago
Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.1% on Monday.
benzinga.com
- 3 weeks ago
Compass Pathways stock slip as psilocybin depression trial falls short of expectations
Shares of Compass Pathways Plc plunged as much as 37% during pre-market trading on Monday after the company's experimental psilocybin treatment for a form of hard-to-treat depression produced results that, while technically successful, fell short of investor expectations.
invezz.com
- 3 weeks ago
Compass Pathways' depression drug succeeds late-stage trial
Compass Pathways said on Monday its experimental psilocybin-based therapy helped significantly reduce symptoms of difficult-to-treat depression in a late-stage study.
reuters.com
- 3 weeks ago
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint is the difference in change from baseline in the Montgomery.
businesswire.com
- 3 weeks ago
Meta to roll out AI-powered ad creation by late 2025, says WSJ
Meta Platforms Inc (NASDAQ:META, ETR:FB2A, SWX:FB) is planning to let brands fully create and target ads using its artificial intelligence tools by the end of 2025, according to a report in the Wall Street Journal. Citing people familiar with the plans, the report says advertisers will be able to provide a product image and budget, and Meta’s AI will handle everything from generating the content, including text, images and video, to targeting users across Facebook and Instagram. Meta already uses AI to customise ads and suggest variations, but the new tools would go further by offering real-time personalisation based on factors like location. The company is also working on automating budget recommendations. With 3.43 billion global users across its apps, Meta sees advanced AI tools as a way to deliver ad results at scale. The move comes as rivals such as Snap, Pinterest and Reddit ramp up their own AI offerings in an increasingly competitive digital ad market. atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company’s clinical development progress in 2025, highlighting multiple upcoming trial readouts. Proactive: Hello, you're watching Proactive. Joining me is atai Life Sciences CEO and co-founder Dr Srinivas Rao. Srinivas, very good to speak with you. You've had a very busy start to 2025. Let's start off with the positive topline data of part two of the Beckley Psytech’s Phase 2a trial of BPL-003. It looks pretty encouraging. Dr Srinivas Rao: Yeah. Well, thanks for having me on. Yeah, we're very excited by that. So this is a continuation of a Phase 2a that we reported the results on last year actually. That was a single administration of BPL-003 in folks who were not taking an SSRI at that time. This is the continuation with those patients that are currently on an SSRI. Once again, we saw very good safety and tolerability and very robust efficacy in this cohort. So certainly important data as we move forward into Phase 3 with this program. The next step here is we're waiting for the results from the large Phase 2b trial that's currently ongoing. And if those results are as encouraging as the ones you just mentioned, when would you be expecting to go ahead with the Phase 3 trial? I mean, we haven't officially guided on that. And of course, the reason for that is it's going to depend upon the results as well as discussions with the FDA. But generally speaking, we can anticipate something starting sometime next year — obviously, sort of middle of next year, perhaps a little later. So you mentioned data from the Phase 2b study, which is expected in the middle of the year. Srinivas, lots of key readouts are expected this year and going into 2026. Take us through some of the other important ones. Yeah, we've got quite a few coming up. So we have the BPL-003 Phase 2b that we were talking about now — that's mid-year. RL-007, the large Phase 2b in cognitive impairment in schizophrenia, also in the middle of this year. Sort of right on top of this one, we’ll see which one comes first. And then early next year, the VLS-01 Illumina study that's currently ongoing should be reading out as well. We just recently initiated a Phase 2a study of EMP-01 in social anxiety disorder. That too is expected to read out in the first quarter of next year. And you announced the dosing of the first patients in that EMP-01 trial. Srinivas, tell us more about the trial and what it’s targeted at? Yeah, I mean again, it's an exploratory study. We wanted to go after a different indication. There's really no one focused on social anxiety disorder currently with a psychedelic compound. It’s using EMP-01, which we had reported results on in January or so last year. From our Phase 1, we found some very interesting properties of that compound — specifically that it had these antiketogenic effects like MDMA, but it also had psychedelic effects as well. So, a really interesting profile — a blend of these two classes in many ways. We spent time looking for the appropriate indication for that and ultimately made the decision to move forward with social anxiety disorder. There is some limited data for MDMA in social anxiety disorder, particularly in the autism subset, where social anxiety disorder is quite prominent. We are looking at broader social anxiety disorder with this. The trial broadly is a six-week study, with two administrations of EMP-01 — on day one and then at week four — and then a readout at week six. We're using a regulatory endpoint there, the so-called Liebowitz Social Anxiety Scale (LSAS). Again, very excited to see how this drug performs in this really important patient population, one that has a huge unmet medical need — bigger than depression — and yet has very limited options, at least from the therapeutic options for the treatment. Srinivas, apart from all of those readouts, any other milestones that your investors should be looking out for as 2025 progresses? I think in terms of the things that people will be really focused on, those are the main ones. The readouts are obviously the key right now. Obviously, there are other readouts in the space that we're all looking at. Compass being an important one. We do remain a shareholder in Compass. They have an interim readout that is also middle of this year. First quarter of next year, I believe, is when the totality of the so-called 005 study will read out. So again, that's going to be a big one for the space, of course. Quotes have been lightly edited for clarity and style
https://www.proactiveinvestors.com
- 1 month ago
COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know
COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 2 months ago
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20th, 2025. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the web.
businesswire.com
- 2 months ago
COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Steve Schultz - SVP, IR Kabir Nath - CEO Teri Loxam - CFO Guy Goodwin - Chief Medical Officer Steve Levin - Chief Patient Officer Conference Call Participants Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald Athena Chin - TD Cowen Sumant Kulkarni - Canaccord Genuity Patrick Trucchio - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by.
seekingalpha.com
- 2 months ago
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2025 and provided an update on recent progress across its business. “We eagerly await the upcoming topline 6-week data readout, on track for late June, the first data from our pivotal phase 3 COMP360 program in treatment resistant depression.” said Kabir.
businesswire.com
- 2 months ago
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in.
businesswire.com
- 2 months ago
8. Profile
Summary
COMPASS Pathways plc CMPS
COUNTRY
GB
INDUSTRY
Medical - Care Facilities
MARKET CAP
$ 303 M
Dividend Yield
0.00%
Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Contact
33 Broadwick Street, London, W1F 0DQ
https://compasspathways.com
IPO
Date
Sept. 18, 2020
Employees
166
Officers
Dr. Susan C. Stansfield Ph.D.
Advisor
Mr. Kabir Kumar Nath M.A., M.B.A.
Chief Executive Officer & Director
Dr. Greg Ryslik Ph.D.
Chief Technology Officer
Ms. Lori Englebert M.B.A.
Chief Commercial Officer
Dr. Michael Gold M.D., M.Sc.
Chief Research & Development Officer
Mr. Lars Christian Wilde
Senior Advisor
Dr. Guy Goodwin
Chief Medical Officer
Ms. Teri Loxam M.B.A.
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Mr. Stephen D. Schultz
Senior Vice President of Investor Relations
Ms. Anne Benedict
Chief People Officer